The authors report on the clinical features and imaging studies in a case of metastatic melanoma of the pituitary gland. Cerebral metastatic melanoma and pituitary metastasis from any source are commonly associated with systemic metastasis, whereas pituitary metastatic melanoma without widespread disease dissemination is distinctly rare. This 46-year-old man presented with diabetes insipidus and anterior pituitary dysfunction 5 years after he underwent resection of a cutaneous malignant melanoma of the neck. Magnetic resonance imaging demonstrated the presence of melanin within a sellar tumor mass. Transsphenoidal resection was performed and histopathological examination of tumor material confirmed metastatic melanoma. Postoperative [18F]fluorodeoxyglucose-positron emission tomography revealed no other focus of hypermetabolism in the patient's body.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3171/jns.2003.99.5.0913 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A complication following metastatic melanoma treatment.
Clin Exp Dermatol
January 2025
Department of Dermatology, Queen Elizabeth University Hopistal, Glasgow, UK.
Association of dermoscopic signs of regression in melanocytic lesions with immune checkpoint inhibitor response in metastatic melanoma patients.
J Eur Acad Dermatol Venereol
January 2025
Service de Dermatologie, Hospices Civils de Lyon, ImmuCare, Hôpital Lyon Sud, Oullins-Pierre-Bénite, France.
Combinational therapy of all-trans retinoic acid (ATRA) and sphingomyelin induces apoptosis and cell cycle arrest in B16F10 melanoma cancer cells.
Turk J Biol
October 2024
Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul, Turkiye.
Background/aim: Melanoma arises from the uncontrolled multiplication of melanocytes, and poses an escalating global health concern. Despite the importance of early detection and surgical removal for effective treatment, metastatic melanoma poses treatment challenges, with limited options. Among optional therapies, including chemotherapy and immunotherapy, all-trans retinoic acid (ATRA), a natural metabolite of vitamin A, has shown promise in treating melanoma by inducing differentiation, apoptosis, growth arrest, and immune modulation in melanoma cells.
View Article and Find Full Text PDFPD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024.
Hum Vaccin Immunother
December 2025
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Programmed cell death-1 (PD-1) inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors are considered effective alternatives for the primary treatment of recurrent metastatic cancers. However, they can induce various adverse events affecting multiple organ systems, potentially diminishing patients' quality of life, and even leading to treatment interruptions. Adverse events related to PD-1/PD-L1 inhibitors differ from those associated with CTLA-4 inhibitors and are more commonly observed in the treatment of solid tumors.
View Article and Find Full Text PDFAtezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysis.
Clin Transl Med
January 2025
Department of Urology, Second Hospital of Tianjin Medical University, Tianjin, China.
Background: Atezolizumab plus bevacizumab has shown promising efficacy in advanced mucosal melanoma in the multi-centre phase II study. This report updates 3-year survival outcomes and multi-omics analysis to identify potential response biomarkers.
Methods: Forty-three intention-to-treat (ITT) patients received intravenous administration of atezolizumab and bevacizumab every 3 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!